Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.23 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.9 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.4.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.17NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CC.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BZ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CK.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CM.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.34NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.35NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.1.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAY.2.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CH.1.1.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.36NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BV.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.26NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.33NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CP.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.45NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.5.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.41NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.75.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CR.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DV.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BT.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XMNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.70NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.63NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.4.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.8.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EC.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BM.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XLNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BD.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.87 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.23.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XNNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.111 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BM.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.31NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.30NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CG.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used